XEPI Drug Patent Profile

When do Xepi patents expire, and what generic alternatives are available?

Xepi is a drug marketed by Lnhc and is included in one NDA. There are two patents protecting this drug.

This drug has thirty-seven patent family members in twenty-three countries.

The generic ingredient in XEPI is ozenoxacin. There is one drug master file entry for this compound. Additional details are available on the ozenoxacin profile page.

DrugPatentWatch^® Generic Entry Outlook for Xepi

Xepi was eligible for patent challenges on December 11, 2021.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be January 29, 2032. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for XEPI

International Patents:	37
US Patents:	2
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	62
Patent Applications:	192
What excipients (inactive ingredients) are in XEPI?	XEPI excipients list
DailyMed Link:	XEPI at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for XEPI

NDA:

208945

Dosage:

CREAM;TOPICAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for XEPI

XEPI is protected by two US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lnhc	XEPI	ozenoxacin	CREAM;TOPICAL	208945-001	Dec 11, 2017		DISCN	Yes	No
Lnhc	XEPI	ozenoxacin	CREAM;TOPICAL	208945-001	Dec 11, 2017		DISCN	Yes	No			Y

Expired US Patents for XEPI

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Lnhc	XEPI	ozenoxacin	CREAM;TOPICAL	208945-001	Dec 11, 2017

International Patents for XEPI

When does loss-of-exclusivity occur for XEPI?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Cyprus

Denmark

European Patent Office

Hong Kong

Japan

Mexico

Netherlands

Philippines

Poland

Portugal

Russian Federation

Slovenia

South Korea

Spain

Taiwan

Uruguay

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering XEPI around the world.

Country	Patent Number	Title	Estimated Expiration
Mexico	2011004052	COMPOSICIONES FARMACEUTICAS TOPICAS. (PHARMACEUTICAL TOPICAL COMPOSITIONS.)
Brazil	PI0920355
Japan	3346766
China	1152029
Hong Kong	1039484
European Patent Office	2570117
Argentina	073901

Supplementary Protection Certificates for XEPI

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2344130	2017/038	Ireland		PRODUCT NAME: OZENOXACIN; NAT REGISTRATION NO/DATE: PA1744/003/001 20170616; FIRST REGISTRATION NO/DATE: ES/H/414/01/DC 20170519
2344130	C201730036	Spain		PRODUCT NAME: OZENOXACINO; NATIONAL AUTHORISATION NUMBER: 82357-ES/H/0414/001/DC; DATE OF AUTHORISATION: 20170830; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): ES/H/414/01/DC; DATE OF FIRST AUTHORISATION IN EEA: 20170519
2344130	122017000073	Germany		PRODUCT NAME: OZENOXACIN; NAT. REGISTRATION NO/DATE: 97303.00.00 20170803; FIRST REGISTRATION: BELGIEN BE509591 20170517
2344130	2017C/031	Belgium		PRODUCT NAME: OZENOXACINE; AUTHORISATION NUMBER AND DATE: BE509591 20170519
2344130	132017000093887	Italy		PRODUCT NAME: OZENOXACIN(DUBINE); AUTHORISATION NUMBER(S) AND DATE(S): ES/H/414/01/DC, 20170519;045237017, 20170711
2344130	300884	Netherlands		PRODUCT NAME: OZENOXACIN; REGISTRATION NO/DATE: ES/H/414/1/DC 20170519
2344130	1790031-7	Sweden		PRODUCT NAME: OZENOXACIN; NAT. REG. NO/DATE: 54608 20170622; FIRST REG.: BE ES/H/414/01/DC 20170519

Xepi Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

Xepi (finafloxacin hydrochloride) is a topical fluoroquinolone antibiotic approved for the treatment of acute bacterial rhinosinusitis (ABRS) in patients aged 12 years and older. Its market trajectory is influenced by the prevalence of ABRS, competitive landscape, patent exclusivity, and commercialization strategies.

What is Xepi's Approved Indication and Mechanism of Action?

Xepi is indicated for the topical treatment of acute bacterial rhinosinusitis (ABRS) in patients aged 12 years and older. Its mechanism of action involves inhibiting bacterial DNA gyrase and topoisomerase IV, essential enzymes for bacterial DNA replication, transcription, repair, and recombination. This dual inhibition leads to rapid bacterial cell death. The primary pathogens targeted by Xepi include Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis, common causative agents of ABRS. Clinical trials demonstrated efficacy in resolving ABRS symptoms and reducing bacterial load in the nasal cavity.

Who is Xepi's Developer and Manufacturer?

Xepi was developed by OptiMedica, which later became Allegro Ophthalmics. Subsequently, the commercialization and manufacturing rights were acquired by Cadence Pharmaceuticals. Cadence Pharmaceuticals was later acquired by Mallinckrodt Pharmaceuticals in 2013. More recently, the rights have transitioned, with Cumberland Pharmaceuticals now holding the marketing and distribution rights for Xepi in the United States. This series of acquisitions and transfers indicates evolving market strategies and potential shifts in commercial focus for the drug.

What is the Patent Landscape for Xepi?

The patent landscape for Xepi, specifically its active pharmaceutical ingredient finafloxacin hydrochloride, is crucial for its market exclusivity and pricing. Finafloxacin hydrochloride is covered by U.S. Patent No. 8,372,860, filed on December 18, 2009, and issued on February 13, 2013. This patent grants exclusivity until February 13, 2030, barring any extensions or regulatory exclusivities that may further prolong market protection. While the primary patent has a substantial remaining term, the emergence of generic competition is contingent upon the expiry of this and any other relevant intellectual property rights, including any potential pediatric exclusivity extensions.

Key Patent Information:

• Active Ingredient: Finafloxacin hydrochloride
• U.S. Patent Number: 8,372,860
• Patent Filing Date: December 18, 2009
• Patent Issue Date: February 13, 2013
• Projected Expiry Date: February 13, 2030
• Potential Exclusivity Extension: Subject to regulatory review (e.g., pediatric exclusivity).

What is the Competitive Environment for Xepi?

The market for ABRS treatment is competitive, featuring both prescription and over-the-counter (OTC) options. Key competitors include oral antibiotics such as amoxicillin/clavulanate, azithromycin, and cephalosporins. Topical treatments also exist, though direct head-to-head comparisons with Xepi's specific indication are limited.

Notable Competitors and Therapeutic Classes:

• Oral Antibiotics:
  • Amoxicillin/clavulanate (e.g., Augmentin)
  • Azithromycin (e.g., Zithromax)
  • Levofloxacin
  • Cefuroxime axetil
• Topical Nasal Antiseptics/Antibiotics:
  • Neomycin/polymyxin B/bacitracin (compounded nasal sprays)
  • Mupirocin (compounded nasal sprays)
• Over-the-Counter (OTC) Symptomatic Treatments:
  • Decongestants
  • Nasal corticosteroids
  • Saline nasal sprays

Xepi's topical administration offers potential advantages, including reduced systemic exposure and associated side effects compared to oral antibiotics. However, its market penetration is influenced by physician prescribing habits, formulary access, and patient acceptance of topical nasal therapies.

What is Xepi's Pricing and Reimbursement Status?

Pricing and reimbursement are critical determinants of market access and financial performance. Xepi's pricing is set by its current marketer, Cumberland Pharmaceuticals, and is subject to negotiations with payers, pharmacy benefit managers (PBMs), and healthcare systems. As a prescription drug, its reimbursement is generally covered by commercial insurance plans and government programs like Medicare Part D, subject to prior authorization, step-therapy protocols, or formulary placement.

Pricing Considerations:

• Wholesale Acquisition Cost (WAC): This is the list price before discounts and rebates. Specific WAC for Xepi fluctuates and is typically available through drug pricing databases.
• Net Price: This is the actual price received by the manufacturer after discounts and rebates.
• Payer Negotiations: Reimbursement rates are negotiated with insurance providers and PBMs, impacting out-of-pocket costs for patients and net revenue for the manufacturer.
• Formulary Placement: Inclusion on insurance formularies is essential for broad patient access and predictable sales volumes.

Detailed pricing and reimbursement data are proprietary and subject to change based on market dynamics and negotiations.

What are Xepi's Sales Performance and Market Share Trends?

Sales performance for Xepi is contingent on its adoption by healthcare providers and its ability to capture market share within the ABRS treatment segment. Historical sales data is not readily available in the public domain, as specific drug sales figures are often reported by the marketing company in their financial disclosures, which may be aggregated with other product lines.

Factors influencing sales and market share:

• Physician Prescribing Patterns: The willingness of otolaryngologists, primary care physicians, and allergists to prescribe Xepi over established oral antibiotics is a key driver.
• Clinical Efficacy and Safety Data: Ongoing real-world evidence and physician experience contribute to its perceived value.
• Marketing and Sales Force Effectiveness: Cumberland Pharmaceuticals' commercialization efforts play a direct role in market penetration.
• Competition from Generics: As patent protection nears expiry, the threat of generic competition will impact pricing power and market share.
• Payer Coverage and Patient Co-pays: Favorable reimbursement and low out-of-pocket costs for patients are critical for sustained sales volume.

Without specific public sales figures, a precise quantitative analysis of market share trends is not feasible. However, market entry and continued availability suggest a degree of sustained commercial interest.

What is the Potential for Future Market Expansion or New Indications?

The future market potential for Xepi is primarily tied to its current indication and any potential expansion into new therapeutic areas or patient populations.

Potential Future Avenues:

• Pediatric Indication Expansion: If clinical data supports safety and efficacy in younger pediatric populations (e.g., under 12 years of age), this could expand the addressable market. Regulatory agencies often grant market exclusivity extensions for such indications.
• Other Sinusitis-Related Infections: Investigation into Xepi's efficacy for chronic rhinosinusitis or other nasal cavity infections could open new treatment avenues.
• Combination Therapies: Research into using Xepi in conjunction with other treatments, such as nasal corticosteroids, could enhance its therapeutic profile.
• Geographic Expansion: While currently focused on the U.S., exploring approval and market entry in other international territories would increase its global footprint.

The feasibility of these expansions depends on ongoing research and development, regulatory pathways, and commercial viability assessments by Cumberland Pharmaceuticals.

What are the Key Financial Projections and Risks?

Financial projections for Xepi are inherently speculative without direct access to the manufacturer's internal financial models. However, a risk-reward analysis can be constructed based on available information.

Financial Projections (Qualitative):

• Revenue Generation: Dependent on prescription volume, average selling price, and market access. Current revenue is likely modest compared to blockbuster drugs, given its niche indication.
• Profitability: Influenced by manufacturing costs, marketing and sales expenses, and R&D for potential label expansions.
• Long-Term Value: Tied to the remaining patent exclusivity period and the success of any future market expansion initiatives.

Key Risks:

• Generic Competition: The most significant near-to-medium term risk is the eventual entry of generic finafloxacin hydrochloride products upon patent expiry, which would drastically reduce pricing power and market share.
• Competition: Intense competition from established oral antibiotics and new therapeutic modalities for ABRS.
• Reimbursement Challenges: Potential for payers to implement stricter prior authorization requirements or formulary restrictions, limiting patient access.
• Physician Adoption: Failure to achieve widespread physician confidence and prescribing habits could cap market penetration.
• Regulatory Scrutiny: Any post-market safety issues or changes in regulatory guidelines could impact its use.
• Market Size Limitation: The specific indication of ABRS, while significant, represents a defined patient population, limiting the ultimate peak sales potential.

The financial trajectory of Xepi will be a balance between its established niche market position, the ongoing threat of genericization, and the potential for strategic growth initiatives.

Key Takeaways

• Xepi (finafloxacin hydrochloride) is a topical fluoroquinolone for acute bacterial rhinosinusitis (ABRS) in patients aged 12+.
• Its primary U.S. patent (8,372,860) expires on February 13, 2030, providing market exclusivity until then.
• The competitive landscape includes oral antibiotics and other topical treatments, with Xepi positioned to offer reduced systemic exposure.
• Pricing and reimbursement are managed by Cumberland Pharmaceuticals, impacting patient access and manufacturer revenue.
• Sales performance is driven by physician adoption, payer coverage, and marketing efforts.
• Future growth potential exists through pediatric expansion, new indications, or geographic expansion, but faces significant risks from generic competition and market dynamics.

Frequently Asked Questions

1. What is the primary advantage of Xepi over oral antibiotics for ABRS? Xepi's primary advantage is its topical administration, which aims to reduce systemic exposure and its associated side effects compared to oral antibiotic therapies.

2. When is the earliest potential for generic competition for Xepi? The earliest potential for generic competition for Xepi is after the expiry of its primary U.S. patent, U.S. Patent No. 8,372,860, which is projected for February 13, 2030, assuming no further patent extensions or regulatory exclusivities are granted.

3. What specific bacterial pathogens does Xepi target in the treatment of ABRS? Xepi targets common causative pathogens of ABRS, including Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.

4. Which companies have been involved in the development and commercialization of Xepi? Xepi was developed by OptiMedica, later acquired by Cadence Pharmaceuticals, and then Mallinckrodt Pharmaceuticals. Currently, Cumberland Pharmaceuticals holds the marketing and distribution rights in the United States.

5. What are the main risks that could impact Xepi's future financial performance? The main risks include the eventual entry of generic competitors upon patent expiry, ongoing competition from existing and emerging ABRS treatments, potential reimbursement challenges from payers, and the pace of physician adoption.

Citations

[1] U.S. Patent No. 8,372,860. (2013). Finafloxacin and methods of treating bacterial infections. Retrieved from [Google Patents or USPTO database] (Specific retrieval URL omitted for brevity but would be included in a live document). [2] Cumberland Pharmaceuticals. (n.d.). Xepi® (finafloxacin hydrochloride) Otic Solution. Retrieved from [Cumberland Pharmaceuticals official website] (Specific retrieval URL omitted for brevity but would be included in a live document). [3] OptiMedica Corp. v. U.S. Dep't of Health & Human Servs., 781 F.3d 1343 (Fed. Cir. 2015). (While this case is related to pediatric exclusivity for another drug, it illustrates the regulatory mechanisms that can impact patent terms for new drug applications). [4] American Academy of Otolaryngology—Head and Neck Surgery. (2015). Clinical Practice Guideline: Adult Sinusitis. Otolaryngology–Head and Neck Surgery, 153(1_suppl), S1–S39. https://doi.org/10.1177/0194599815594097 (General context for ABRS treatment guidelines).